Pronosthyc: Prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF Network
Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases have a heterogeneous prognosis, spanning from indolent to rapidly progressing disease. Our aim is to assess overall survival (OS) in RAI-R DTC patients and to identify the associated prognostic factors. A retrospective multicentric (ENDOCAN-TUTHYREF Network) analysis of consecutive cases of distant metastatic RAI-R DTC, diagnosed between 1990 and 2022, was performed. Survival was estimated using the Kaplan-Meier method and prognostic factors were assessed by Cox's model. Our cohort included 899 patients (52.1% females, median age 65 years [20–90] at RAI-R DTC diagnosis). Median follow-up was 4.8 years [0.1–40.1], primary tumour resection in 95.9%. Histotypes were papillary (55.6%), follicular (12.2%), oncocytic (10.6%) and poorly differentiated (21.6%). Metastases diagnosis was synchronous to primary in 39.4%, macroscopic (>1 cm) in 48.2% and multiple in 83.4% of the cases; 521 (58%) patients were treated with systemic therapies. In 332 (37%) patients, driver mutation status was assessed: 63% BRAFV600E, 29.5% RAS (21% NRAS, 5% HRAS, 3.5% KRAS) mutations and 6% gene fusions (3% RET, 2% NTRK, 1% ALK). After RAI-R DTC diagnosis, median OS was 9.5 years, (5-, 10-year OS rates; 74.8%, 48.1% respectively). Prognostic factors independently associated with worse OS were age ≥55 years (HR = 2.54; 95%CI = 1.84–3.57), multiple metastatic sites (HR = 2.80; 95%CI = 1.80–4.64), macroscopic metastases (HR = 1.98; 95%CI = 1.54–2.55), positive 18 FDG-PET uptake (HR = 2.08; 95%CI = 1.30–3.52), while better OS was associated to primary tumor resection (HR = 0.50; 95%CI = 0.31–0.86), differentiated tumor type (HR = 0.53; 95%CI = 0.41–0.68), metachronous metastatic presentation (HR = 0.64; 95%CI = 0.50–0.82). RAI-R DTC prognosis can be stratified by some simple independent prognostic factors of OS.
Authors
- S. Hescot (ORCID: https://orcid.org/0000-0002-0869-3003)
- J. Wassermann
- F. Illouz (ORCID: https://orcid.org/0000-0002-5676-0127)
- M. Laramas
- J. Hadoux
- F. Borson-Chazot
- Camille Buffet (ORCID: https://orcid.org/0000-0003-1389-4157)
- N. Roudaut
- I. Borget
- M. Abdelouahab
- Livia Lamartina (ORCID: https://orcid.org/0000-0003-3640-1204)
- Alfonso Sagnella (ORCID: https://orcid.org/0000-0003-2247-9027)
- Chengjian Cao
- Hélène Lasolle (ORCID: https://orcid.org/0000-0002-5027-7660)
- Y. Godbert
- Delphine Drui
- C. Sage
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Lyon College (US)
- Institut Gustave Roussy (FR)
- Sorbonne Université (FR)
- Centre de Recherche en Neurosciences de Lyon (FR)
- Centre de Recherche Jean Pierre Aubert (FR)
- Library Network (US)
- Centre Hospitalier Universitaire d'Angers (FR)
- Institut de Myologie (FR)
- Laboratoire d’Imagerie Biomédicale (FR)
- Laboratoire d'études sur les monothéismes (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Institut Bergonié (FR)
- Institut du Thorax (FR)
- Cloud Computing Center (CN)
- Laboratoire de Sciences de la Terre (FR)
- Hôpital Laennec (FR)
- Action Network (US)
- Hôpital Maison Blanche (FR)
- Network Group (Czechia) (CZ)
- Institut Curie (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Annales d Endocrinologie
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.ando.2024.08.111
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.72